Ironwood Pharmaceuticals, Inc. - (IRWD) News
Filter IRWD News Items
IRWD News Results
|Loading, please wait...|
IRWD News Highlights
- IRWD's 30 day story count now stands at 11.
- Over the past 15 days, the trend for IRWD's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- The most mentioned tickers in articles about IRWD are DRUG, EXEL and ID.
Latest IRWD News From Around the Web
Below are the latest news stories about Ironwood Pharmaceuticals Inc that investors may wish to consider to help them evaluate IRWD as an investment opportunity.
Ironwood (IRWD) witnesses flat year-over-year sales growth. Its fourth-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.
Ironwood Pharmaceuticals, Inc. (IRWD) CEO Thomas McCourt on Q4 2021 Results - Earnings Call Transcript
Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2021 Earnings Conference Call February 17, 2022 08:30 A.M. ET Company Participants Matt Roache - Director of IR Thomas McCourt - CEO Michael Shetzline - CMO and Head of R&D Sravan K. Emany - CFO Conference Call Participants Boris Peaker - Cowen & Company Eric...
Ironwood Pharmaceuticals press release (IRWD): Q4 Non-GAAP EPS of $0.27 misses by $0.07.Revenue of $117.13M (+0.4% Y/Y) beats by $6.96M.Guidance: FY22 The company expects the…
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD ) reported Q4 FY21 sales of $117.1 million , compared to $116.7 million in Q4 FY20, beating the consensus of $109.87 million. Ironwood recorded $113.7 million in collaboration revenue in Q4 related to sales of LINZESS in the U.S., a 2.7% Y/Y increase, and $3.4 million in royalties and other revenue. Total … Full story available on Benzinga.com
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021
BOSTON, February 17, 2022--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its fourth quarter and full year 2021 results.
Ironwood Pharmaceuticals (NASDAQ:IRWD) is scheduled to announce Q4 earnings results on Thursday, February 17th, before market open.The consensus EPS Estimate is $0.34 (-5.6% Y/Y) and…
Let us take a look at four biotech or drug companies - RGEN, IRWD, EXEL and LGND - due to release their quarterly results on Feb 16.
In this article, we discuss 10 cheap pharmaceutical stocks for 2022. If you want to skip our detailed analysis of these stocks, go directly to 5 Cheap Pharmaceutical Stocks For 2022. The pharma industry is in the midst of a fundamental transformation as disruptive technologies like artificial intelligence, machine learning, and natural language processing become […]
Is Ironwood Pharmaceuticals (IRWD) a great pick from the value investor's perspective right now? Read on to know more.
BOSTON, February 03, 2022--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2021 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 17, 2022. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) or (240) 789-2701 (international) using conference ID number and event passcode 4671230. To access the webcast, please visit the Investors section of Ironwood’s